MedTrace Logo

Functional Investigation of Endothelial Function and Regenerative Cell Exhaustion

NCT06108388 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2023-11-13

No results posted yet for this study

Summary

FIERCE is an observational cross-sectional study. Approximately 90 individuals living with type 2 diabetes (T2D) and/or individuals living without diabetes will be randomized (2:1).

The primary objective of this trial is to determine if there are differences in the content and function of circulating vascular regenerative (VR) progenitor cell subsets isolated from individuals living with T2D versus individuals not living with T2D. The main question this study aims to answer is: Does T2D compromise or enhance VR cell functionality?

Each participant will be asked to provide a single blood sample. Blood samples will be processed to enumerate the number of vessel-repairing cells and determine the functionality of the different subtypes of vessel-repairing cells.

Conditions

  • Diabetes Mellitus, Type 2

Sponsors & Collaborators

  • Unity Health Toronto

    collaborator OTHER

  • University of Western Ontario, Canada

    collaborator OTHER

  • Canadian Medical and Surgical Knowledge Translation Research Group

    lead OTHER

Principal Investigators

  • Subodh Verma, MD, PhD · Unity Health Toronto

  • David A Hess, PhD · Robarts Research Institute, London, Ontario

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-30
Primary Completion
2025-12-31
Completion
2026-06-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06108388 on ClinicalTrials.gov